Skip to content

Schering-Plough SGP Financing Cash Flow

Financing Cash Flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$530M-94.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$802.2M+26.3%
Glaukos logo
GlaukosGKOS
$15.77M+709%
AbbVie logo
AbbVieABBV
$919M+173%
Bausch + Lomb logo
Bausch + LombBLCO
-$20M-165%
HRO
HarrowHROW
$48.91M+212,561%

Other financials

Income statement

See full
Operating income-$15.4M-108%
Net income-$13.8M-56.6%
EPS (diluted)-$0.69+82.6%

Balance sheet

See full
Cash & equivalents$238.9M+312%
Total debt$1.6M
Total equity$250.1M+463%
Total assets$258.4M

Cash flow

See full
Operating cash flow-$13.5M-65.2%
CapEx$676.0K+312%
Free cash flow-$14.2M-70.0%

Valuation

See full
Market cap$744.23M-23.4%
Enterprise value$506.93M

Returns & leverage

See full
Return on equity-34.3%
Debt / equity
Current ratio38×

Where this comes from

Reported directly by Schering-Plough in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Schering-Plough’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schering-Plough's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schering-Plough's financing cash flow?
Schering-Plough (SGP) reported financing cash flow of $157.76M in Q1 2026.
How has Schering-Plough's financing cash flow changed year-over-year?
Schering-Plough's financing cash flow increased by 214.9% year-over-year, from $50.1M to $157.76M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.